Search for "acetaldehyde" in Full Text gives 75 result(s) in Beilstein Journal of Organic Chemistry.
Beilstein J. Org. Chem. 2014, 10, 1006–1016, doi:10.3762/bjoc.10.100
Graphical Abstract
Figure 1: Phenothiazine–anthraquinone dyad 1, donor-only (2) and acceptor-only (3) models assembled by Ugi 4C...
Scheme 1: Ugi 4CR synthesis of donor–anthraquinone dyads 8.
Scheme 2: Ugi 4CR synthesis of donor-only reference systems 10.
Figure 2: Molecular structure of S(O)-1 (left) (30% ellipsoids, except for the CH3CH2 end of the hexyl group,...
Figure 3: Cyclic voltammogram of dyad 8c (recorded in CH2Cl2, T = 298 K, c (8c) = 0.1 mol·L−1, Pt working ele...
Figure 4: DFT-computed (B3LYP, 6-311G*) frontier molecular orbitals HOMO (bottom) and LUMO (top) of the pheno...
Figure 5: Normalized absorption spectra of the phenothiazine–anthraquinone dyad 8c (recorded in CH2Cl2, c (8c...
Figure 6: Absorption spectra of Do–anthraquinone dyads 8c (top) and 8e (bottom) with the corresponding refere...
Figure 7: Normalized absorption and emission spectra of Ugi-donor compounds 2 and 10 (recorded in CH2Cl2, T =...
Figure 8: Emission spectra of donor-only system 2 phenothiazine–anthraquinone dyads 8a,b (top), and the donor...
Beilstein J. Org. Chem. 2014, 10, 722–731, doi:10.3762/bjoc.10.66
Graphical Abstract
Scheme 1: Synthesis of (trifluoromethyl)phosphinic acid (1) and ethyl and isopropyl esters 2–4. Reagents and ...
Scheme 2: Three-component Kabachnik–Fields reaction of CF3(H)P(O)(OiPr) (2) with formaldehyde and dibenzylami...
Scheme 3: Three-component synthesis of CF3 containing α-aminophosphinic acids 14a,b. Reagents and conditions:...
Scheme 4: Interaction of the acid 1 with tert-butyl benzylidenecarbamate (21). Reagents and conditions: i) an...
Scheme 5: Interaction of the acids 1 and 6 with ethyl 2-[(tert-butoxycarbonyl)imino]acetate (22). Reagents an...
Scheme 6: Transformation of the ester 24 into the appropriate free acid 25. Reagents and conditions: i) two f...
Scheme 7: Reaction of the acids (1) and (6) with methyl 2-imino-3-methylbutanoate (26). Reagents and conditio...
Scheme 8: Interaction of the acid 1 with ethyl 2-(tert-butoxycarbonylamino)acrylate (29). Reagents and condit...
Scheme 9: Interaction of a mixture of the esters 3 and 4 with 2-acetamidoacrylic acid (33). Reagents and cond...
Scheme 10: Interaction of a mixture of the acid 1 with diethyl acetaminomethylenemalonate (38). Reagents and c...
Beilstein J. Org. Chem. 2014, 10, 544–598, doi:10.3762/bjoc.10.50
Graphical Abstract
Scheme 1: The proposed mechanism of the Passerini reaction.
Scheme 2: The PADAM-strategy to α-hydroxy-β-amino amide derivatives 7. An additional oxidation provides α-ket...
Scheme 3: The general accepted Ugi-mechanism.
Scheme 4: Three commonly applied Ugi/cyclization approaches. a) UDC-process, b) UAC-sequence, c) UDAC-combina...
Scheme 5: Ugi reaction that involves the condensation of Armstrong’s convertible isocyanide.
Scheme 6: Mechanism of the U-4C-3CR towards bicyclic β-lactams.
Scheme 7: The Ugi 4C-3CR towards oxabicyclo β-lactams.
Scheme 8: Ugi MCR between an enantiopure monoterpene based β-amino acid, aldehyde and isocyanide resulting in...
Scheme 9: General MCR for β-lactams in water.
Scheme 10: a) Ugi reaction for β-lactam-linked peptidomimetics. b) Varying the β-amino acid resulted in β-lact...
Scheme 11: Ugi-4CR followed by a Pd-catalyzed Sn2 cyclization.
Scheme 12: Ugi-3CR of dipeptide mimics from 2-substituted pyrrolines.
Scheme 13: Joullié–Ugi reaction towards 2,5-disubstituted pyrrolidines.
Scheme 14: Further elaboration of the Ugi-scaffold towards bicyclic systems.
Scheme 15: Dihydroxyproline derivatives from an Ugi reaction.
Scheme 16: Diastereoselective Ugi reaction described by Banfi and co-workers.
Scheme 17: Similar Ugi reaction as in Scheme 16 but with different acids and two chiral isocyanides.
Scheme 18: Highly diastereoselective synthesis of pyrrolidine-dipeptoids via a MAO-N/MCR-procedure.
Scheme 19: MAO-N/MCR-approach towards the hepatitis C drug telaprevir.
Scheme 20: Enantioselective MAO-U-3CR procedure starting from chiral pyrroline 64.
Scheme 21: Synthesis of γ-lactams via an UDC-sequence.
Scheme 22: Utilizing bifunctional groups to provide bicyclic γ-lactam-ketopiperazines.
Scheme 23: The Ugi reaction provided both γ- as δ-lactams depending on which inputs were used.
Scheme 24: The sequential Ugi/RCM with olefinic substrates provided bicyclic lactams.
Scheme 25: a) The structural and dipole similarities of the triazole unit with the amide bond. b) The copper-c...
Scheme 26: The Ugi/Click sequence provided triazole based peptidomimetics.
Scheme 27: The Ugi/Click reaction as described by Nanajdenko.
Scheme 28: The Ugi/Click-approach by Pramitha and Bahulayan.
Scheme 29: The Ugi/Click-combination by Niu et al.
Scheme 30: Triazole linked peptidomimetics obtained from two separate MCRs and a sequential Click reaction.
Scheme 31: Copper-free synthesis of triazoles via two MCRs in one-pot.
Scheme 32: The sequential Ugi/Paal–Knorr reaction to afford pyrazoles.
Scheme 33: An intramolecular Paal–Knorr condensation provided under basic conditions pyrazolones.
Scheme 34: Similar cyclization performed under acidic conditions provided pyrazolones without the trifluoroace...
Scheme 35: The Ugi-4CR towards 2,4-disubstituted thiazoles.
Scheme 36: Solid phase approach towards thiazoles.
Scheme 37: Reaction mechanism of formation of thiazole peptidomimetics containing an additional β-lactam moiet...
Scheme 38: The synthesis of the trisubstituted thiazoles could be either performed via an Ugi reaction with pr...
Scheme 39: Performing the Ugi reaction with DMB-protected isocyanide gave access to either oxazoles or thiazol...
Scheme 40: Ugi/cyclization-approach towards 2,5-disubstituted thiazoles. The Ugi reaction was performed with d...
Scheme 41: Further derivatization of the thiazole scaffold.
Scheme 42: Three-step procedure towards the natural product bacillamide C.
Scheme 43: Ugi-4CR to oxazoles reported by Zhu and co-workers.
Scheme 44: Ugi-based synthesis of oxazole-containing peptidomimetics.
Scheme 45: TMNS3 based Ugi reaction for peptidomimics containing a tetrazole.
Scheme 46: Catalytic cycle of the enantioselective Passerini reaction towards tetrazole-based peptidomimetics.
Scheme 47: Tetrazole-based peptidomimetics via an Ugi reaction and a subsequent sigmatropic rearrangement.
Scheme 48: Resin-bound Ugi-approach towards tetrazole-based peptidomimetics.
Scheme 49: Ugi/cyclization approach towards γ/δ/ε-lactam tetrazoles.
Scheme 50: Ugi-3CR to pipecolic acid-based peptidomimetics.
Scheme 51: Staudinger–Aza-Wittig/Ugi-approach towards pipecolic acid peptidomimetics.
Figure 1: The three structural isomers of diketopiperazines. The 2,5-DKP isomer is most common.
Scheme 52: UDC-approach to obtain 2,5-DKPs, either using Armstrong’s isocyanide or via ethylglyoxalate.
Scheme 53: a) Ugi reaction in water gave either 2,5-DKP structures or spiro compounds. b) The Ugi reaction in ...
Scheme 54: Solid-phase approach towards diketopiperazines.
Scheme 55: UDAC-approach towards DKPs.
Scheme 56: The intermediate amide is activated as leaving group by acid and microwave assisted organic synthes...
Scheme 57: UDC-procedure towards active oxytocin inhibitors.
Scheme 58: An improved stereoselective MCR-approach towards the oxytocin inhibitor.
Scheme 59: The less common Ugi reaction towards DKPs, involving a Sn2-substitution.
Figure 2: Spatial similarities between a natural β-turn conformation and a DKP based β-turn mimetic [158].
Scheme 60: Ugi-based syntheses of bicyclic DKPs. The amine component is derived from a coupling between (R)-N-...
Scheme 61: Ugi-based synthesis of β-turn and γ-turn mimetics.
Figure 3: Isocyanide substituted 3,4-dihydropyridin-2-ones, dihydropyridines and the Freidinger lactams. Bio-...
Scheme 62: The mechanism of the 4-CR towards 3,4-dihydropyridine-2-ones 212.
Scheme 63: a) Multiple MCR-approach to provide DHP-peptidomimetic in two-steps. b) A one-pot 6-CR providing th...
Scheme 64: The MCR–alkylation–MCR procedure to obtain either tetrapeptoids or depsipeptides.
Scheme 65: U-3CR/cyclization employing semicarbazone as imine component gave triazine based peptidomimetics.
Scheme 66: 4CR towards triazinane-diones.
Scheme 67: The MCR–alkylation–IMCR-sequence described by our group towards triazinane dione-based peptidomimet...
Scheme 68: Ugi-4CR approaches followed by a cyclization to thiomorpholin-ones (a) and pyrrolidines (b).
Scheme 69: UDC-approach for benzodiazepinones.
Scheme 70: Ugi/Mitsunobu sequence to BDPs.
Scheme 71: A UDAC-approach to BDPs with convertible isocyanides. The corresponding amide is cleaved by microwa...
Scheme 72: microwave assisted post condensation Ugi reaction.
Scheme 73: Benzodiazepinones synthesized via the post-condensation Ugi/ Staudinger–Aza-Wittig cyclization.
Scheme 74: Two Ugi/cyclization approaches utilizing chiral carboxylic acids. Reaction (a) provided the product...
Scheme 75: The mechanism of the Gewald-3CR includes three base-catalysed steps involving first a Knoevnagel–Co...
Scheme 76: Two structural 1,4-thienodiazepine-2,5-dione isomers by U-4CR/cyclization.
Scheme 77: Tetrazole-based diazepinones by UDC-procedure.
Scheme 78: Tetrazole-based BDPs via a sequential Ugi/hydrolysis/coupling.
Scheme 79: MCR synthesis of three different tricyclic BPDs.
Scheme 80: Two similar approaches both involving an Ugi reaction and a Mitsunobu cyclization.
Scheme 81: Mitsunobu–Ugi-approach towards dihydro-1,4-benzoxazepines.
Scheme 82: Ugi reaction towards hetero-aryl fused 5-oxo-1,4-oxazepines.
Scheme 83: a) Ugi/RCM-approach towards nine-membered peptidomimetics b) Sequential peptide-coupling, deprotect...
Scheme 84: Ugi-based synthesis towards cyclic RGD-pentapeptides.
Scheme 85: Ugi/MCR-approach towards 12–15 membered macrocycles.
Scheme 86: Stereoselective Ugi/RCM approach towards 16-membered macrocycles.
Scheme 87: Passerini/RCM-sequence to 22-membered macrocycles.
Scheme 88: UDAC-approach towards 12–18-membered depsipeptides.
Figure 4: Enopeptin A with its more active derivative ADEP-4.
Scheme 89: a) The Joullié–Ugi-approach towards ADEP-4 derivatives b) Ugi-approach for the α,α-dimethylated der...
Scheme 90: Ugi–Click-strategy for 15-membered macrocyclic glyco-peptidomimetics.
Scheme 91: Ugi/Click combinations provided macrocycles containing both a triazole and an oxazole moiety.
Scheme 92: a) A solution-phase procedure towards macrocycles. b) Alternative solid-phase synthesis as was repo...
Scheme 93: Ugi/cyclization towards cyclophane based macrocycles.
Scheme 94: PADAM-strategy towards eurystatin A.
Scheme 95: PADAM-approach for cyclotheanamide.
Scheme 96: A triple MCR-approach affording RGD-pentapeptoids.
Scheme 97: Ugi-MiBs-approach towards peptoid macrocycles.
Scheme 98: Passerini-based MiB approaches towards macrocycles 345 and 346.
Scheme 99: Macrocyclic peptide formation by the use of amphoteric aziridine-based aldehydes.
Beilstein J. Org. Chem. 2014, 10, 369–383, doi:10.3762/bjoc.10.35
Graphical Abstract
Figure 1: Natural products and other bioactive piperidine derivatives of type B.
Figure 2: Retrosynthetic analysis of piperidines B (X = OH or leaving group, PG = protecting group).
Scheme 1: Synthesis of the protected amino acids 2. (a) KOH for 1b. b) PG–X = Cbz–Cl (1a–c), Boc2O (1d).
Scheme 2: Synthesis of hydroxy ketones 7 (R = Me (a), Bn (b), Ph (c) and EtSMe (d); PG = Cbz (a–c), Boc (d)).
Scheme 3: Synthesis of amides 5e and 5f and ketone 7e.
Scheme 4: Synthesis of amino alcohols syn-9a–d and oxazolidinone 10a. (for 7a–c conditions A: H2 (1 atm), Pd/...
Scheme 5: Competition between the Michaelis–Arbuzow process and the desired cyclodehydration of amino alcohol...
Scheme 6: Initial synthesis of the trans-piperidinol 11a in diminished enantiopurity. aThe amino alcohol 9a o...
Scheme 7: Synthesis of trans-piperidinol 11a in excellent ee.
Scheme 8: Synthesis of L-733,060·HCl.
Beilstein J. Org. Chem. 2014, 10, 127–133, doi:10.3762/bjoc.10.9
Graphical Abstract
Figure 1: Bisamides as building blocks for flavaglins.
Figure 2: (+)-Grandiamide D, gigantamide A and dasyclamide.
Scheme 1: Retrosynthetic analysis: A unified synthetic approach for the synthesis of grandiamide D, dasyclami...
Scheme 2: Preparation of N-(4-aminobutyl)cinnamamide.
Scheme 3: Synthesis of (±)-grandiamide D.
Scheme 4: Asymmetric synthesis of natural (+)-grandiamide D.
Scheme 5: Various approaches for the synthesis of (E)-N-(4-cinnamamidobutyl)-4-((4-methoxybenzyl)oxy)-2-methy...
Scheme 6: Synthesis of dasyclamide.
Beilstein J. Org. Chem. 2013, 9, 2846–2851, doi:10.3762/bjoc.9.320
Graphical Abstract
Figure 1: X-ray crystal structure of 4a.
Scheme 1: Possible mechanism.
Figure 2: Scope of the enantioselective reaction. Reaction conditions: 5a (10 mol %, 0.02 mmol), 1 (0.2 mmol)...
Beilstein J. Org. Chem. 2013, 9, 2265–2319, doi:10.3762/bjoc.9.265
Graphical Abstract
Scheme 1: Scaled industrial processes for the synthesis of simple pyridines.
Scheme 2: Synthesis of nicotinic acid from 2-methyl-5-ethylpyridine (1.11).
Scheme 3: Synthesis of 3-picoline and nicotinic acid.
Scheme 4: Synthesis of 3-picoline from 2-methylglutarodinitrile 1.19.
Scheme 5: Picoline-based synthesis of clarinex (no yields reported).
Scheme 6: Mode of action of proton-pump inhibitors and structures of the API’s.
Scheme 7: Hantzsch-like route towards the pyridine rings in common proton pump inhibitors.
Figure 1: Structures of rosiglitazone (1.40) and pioglitazone (1.41).
Scheme 8: Synthesis of rosiglitazone.
Scheme 9: Syntheses of 2-pyridones.
Scheme 10: Synthesis and mechanism of 2-pyrone from malic acid.
Scheme 11: Polymer-assisted synthesis of rosiglitazone.
Scheme 12: Synthesis of pioglitazone.
Scheme 13: Meerwein arylation reaction towards pioglitazone.
Scheme 14: Route towards pioglitazone utilising tyrosine.
Scheme 15: Route towards pioglitazone via Darzens ester formation.
Scheme 16: Syntheses of the thiazolidinedione moiety.
Scheme 17: Synthesis of etoricoxib utilising Negishi and Stille cross-coupling reactions.
Scheme 18: Synthesis of etoricoxib via vinamidinium condensation.
Figure 2: Structures of nalidixic acid, levofloxacin and moxifloxacin.
Scheme 19: Synthesis of moxifloxacin.
Scheme 20: Synthesis of (S,S)-2,8-diazabicyclo[4.3.0]nonane 1.105.
Scheme 21: Synthesis of levofloxacin.
Scheme 22: Alternative approach to the levofloxacin core 1.125.
Figure 3: Structures of nifedipine, amlodipine and clevidipine.
Scheme 23: Mg3N2-mediated synthesis of nifedipine.
Scheme 24: Synthesis of rac-amlodipine as besylate salt.
Scheme 25: Aza Diels–Alder approach towards amlodipine.
Scheme 26: Routes towards clevidipine.
Figure 4: Examples of piperidine containing drugs.
Figure 5: Discovery of tiagabine based on early leads.
Scheme 27: Synthetic sequences to tiagabine.
Figure 6: Structures of solifenacin (2.57) and muscarine (2.58).
Scheme 28: Enantioselective synthesis of solifenacin.
Figure 7: Structures of DPP-4 inhibitors of the gliptin-type.
Scheme 29: Formation of inactive diketopiperazines from cis-rotameric precursors.
Figure 8: Co-crystal structure of carmegliptin bound in the human DPP-4 active site (PDB 3kwf).
Scheme 30: Improved route to carmegliptin.
Figure 9: Structures of lamivudine and zidovudine.
Scheme 31: Typical routes accessing uracil, thymine and cytosine.
Scheme 32: Coupling between pyrimidones and riboses via the Vorbrüggen nucleosidation.
Scheme 33: Synthesis of lamivudine.
Scheme 34: Synthesis of raltegravir.
Scheme 35: Mechanistic studies on the formation of 3.22.
Figure 10: Structures of selected pyrimidine containing drugs.
Scheme 36: General preparation of pyrimidines and dihydropyrimidones.
Scheme 37: Synthesis of imatinib.
Scheme 38: Flow synthesis of imatinib.
Scheme 39: Syntheses of erlotinib.
Scheme 40: Synthesis of erlotinib proceeding via Dimroth rearrangement.
Scheme 41: Synthesis of lapatinib.
Scheme 42: Synthesis of rosuvastatin.
Scheme 43: Alternative preparation of the key aldehyde towards rosuvastatin.
Figure 11: Structure comparison between nicotinic acetylcholine receptor agonists.
Scheme 44: Syntheses of varenicline and its key building block 4.5.
Scheme 45: Synthetic access to eszopiclone and brimonidine via quinoxaline intermediates.
Figure 12: Bortezomib bound in an active site of the yeast 20S proteasome ([114], pdb 2F16).
Scheme 46: Asymmetric synthesis of bortezomib.
Figure 13: Structures of some prominent piperazine containing drugs.
Figure 14: Structural comparison between the core of aplaviroc (4.35) and a type-1 β-turn (4.36).
Scheme 47: Examplary synthesis of an aplaviroc analogue via the Ugi-MCR.
Scheme 48: Syntheses of azelastine (5.1).
Figure 15: Structures of captopril, enalapril and cilazapril.
Scheme 49: Synthesis of cilazapril.
Figure 16: Structures of lamotrigine, ceftriaxone and azapropazone.
Scheme 50: Synthesis of lamotrigine.
Scheme 51: Alternative synthesis of lamotrigine (no yields reported).
Figure 17: Structural comparison between imiquimod and the related adenosine nucleoside.
Scheme 52: Conventional synthesis of imiquimod (no yields reported).
Scheme 53: Synthesis of imiquimod.
Scheme 54: Synthesis of imiquimod via tetrazole formation (not all yields reported).
Figure 18: Structures of various anti HIV-medications.
Scheme 55: Synthesis of abacavir.
Figure 19: Structures of diazepam compared to modern replacements.
Scheme 56: Synthesis of ocinaplon.
Scheme 57: Access to zaleplon and indiplon.
Scheme 58: Different routes towards the required N-methylpyrazole 6.65 of sildenafil.
Scheme 59: Polymer-supported reagents in the synthesis of key aminopyrazole 6.72.
Scheme 60: Early synthetic route to sildenafil.
Scheme 61: Convergent preparations of sildenafil.
Figure 20: Comparison of the structures of sildenafil, tadalafil and vardenafil.
Scheme 62: Short route to imidazotriazinones.
Scheme 63: Alternative route towards vardenafils core imidazotriazinone (6.95).
Scheme 64: Bayer’s approach to the vardenafil core.
Scheme 65: Large scale synthesis of vardenafil.
Scheme 66: Mode of action of temozolomide (6.105) as methylating agent.
Scheme 67: Different routes to temozolomide.
Scheme 68: Safer route towards temozolomide.
Figure 21: Some unreported heterocyclic scaffolds in top market drugs.
Beilstein J. Org. Chem. 2013, 9, 2168–2179, doi:10.3762/bjoc.9.254
Graphical Abstract
Scheme 1: Phenylserine synthesis.
Figure 1: Activity loss of TA immobilized by two different methods and as a free enzyme at 80 °C. Reproduced ...
Figure 2: Degree of immobilization versus incubation time.
Figure 3: Batch reaction using free enzyme. Reaction conditions: Reaction volume (10 mL), TA (2.7 mg, specifi...
Figure 4: Product inhibition study.
Figure 5: Effect of temperature on product yield. Reaction conditions: Reaction volume (0.250 mL), TA (1.1 mg...
Figure 6: Effect of flow rates on yield for immobilized enzymes in a packed bed microreactor (70 °C). Reactio...
Figure 7: Effect of residence time on yield for free enzymes in a Teflon tube microreactor at 70 °C. Reaction...
Figure 8: Long term enzyme stability at 70 °C. Reaction conditions: Reaction volume (0.250 mL), TA (1.1 mg, s...
Scheme 2: Synthesis of chiral α-aminoalcohol by telescoping aldolase reaction with decarboxylation.
Figure 9: Direct immobilization.
Figure 10: Indirect immobilization.
Figure 11: Flow reaction set-up using free enzyme.
Figure 12: Experimental setup for packed be microreactor.
Figure 13: Analysis of the four isomers of phenylserine on a chiral column.
Beilstein J. Org. Chem. 2013, 9, 1977–2001, doi:10.3762/bjoc.9.234
Graphical Abstract
Scheme 1: Amine radical cations’ mode of reactivity.
Scheme 2: Reductive quenching of photoexcited Ru complexes by Et3N.
Scheme 3: Photoredox aza-Henry reaction.
Scheme 4: Formation of iminium ions using BrCCl3 as stoichiometric oxidant.
Scheme 5: Oxidative functionalization of N-aryltetrahydroisoquinolines using Eosin Y.
Scheme 6: Synthetic and mechanistic studies of Eosin Y-catalyzed aza-Henry reaction.
Scheme 7: Oxidative functionalization of N-aryltetrahydroisoquinolines using RB and GO.
Scheme 8: Merging Ru-based photoredox catalysis and Lewis base catalysis for the Mannich reaction.
Scheme 9: Merging Au-based photoredox catalysis and Lewis base catalysis for the Mannich reaction.
Scheme 10: Merging Ru-based photoredox catalysis and Cu-catalyzed alkynylation reaction.
Scheme 11: Merging Ru-based photoredox catalysis and NHC catalysis.
Scheme 12: 1,3-Dipolar cycloaddition of photogenically formed azomethine ylides.
Scheme 13: Plausible mechanism for photoredox 1,3-dipolar cycloaddition.
Scheme 14: Photoredox-catalyzed cascade reaction for the synthesis of fused isoxazolidines.
Scheme 15: Plausible mechanism for the photoredox-catalyzed cascade reaction.
Scheme 16: Photoredox-catalyzed α-arylation of glycine derivatives.
Scheme 17: Photoredox-catalyzed α-arylation of amides.
Scheme 18: Intramolecular interception of iminium ions by sulfonamides.
Scheme 19: Intramolecular interception of iminium ions by alcohols and sulfonamides.
Scheme 20: Intermolecular interception of iminium ions by phosphites.
Scheme 21: Photoredox-catalyzed oxidative phosphonylation by Eosin Y.
Scheme 22: Conjugated addition of α-amino radicals to Michael acceptors.
Scheme 23: Conjugated addition of α-amino radicals to Michael acceptors assisted by a Brønsted acid.
Scheme 24: Conjugated addition of α-amino radicals derived from anilines to Michael acceptors.
Scheme 25: Oxygen switch between two pathways involving α-amino radicals.
Scheme 26: Interception of α-amino radicals by azodicarboxylates.
Scheme 27: α-Arylation of amines.
Scheme 28: Plausible mechanism for α-arylation of amines.
Scheme 29: Photoinduced C–C bond cleavage of tertiary amines.
Scheme 30: Photoredox cleavage of C–C bonds of 1,2-diamines.
Scheme 31: Proposed mechanism photoredox cleavage of C–C bonds.
Scheme 32: Intermolecular [3 + 2] annulation of cyclopropylamines with olefins.
Scheme 33: Proposed mechanism for intermolecular [3 + 2] annulation.
Scheme 34: Photoinduced clevage of N–N bonds of aromatic hydrazines and hydrazides.
Beilstein J. Org. Chem. 2013, 9, 1668–1676, doi:10.3762/bjoc.9.191
Graphical Abstract
Figure 1: Formal, topological approach to derive coarctate reactions from pericyclic reactions; p, q: number ...
Figure 2: Stereochemistry of coarctate reactions derived from a Hückel (top) and a Möbius band (bottom). The ...
Scheme 1: Coarctate fragmentation of the spiroozonide derived from methylenecyclopropane.
Scheme 2: Photochemically and thermally allowed coarctate fragmentations of spiroketals.
Scheme 3: Precursors used in this study.
Figure 3: Difference infrared spectrum, showing the changes in the IR spectrum after photolysis (λexc = 254 n...
Figure 4: Infrared spectrum obtained upon FVP of 1 at T = 1143 K and trapping the pyrolysate in solid argon a...
Figure 5: Infrared spectrum obtained upon FVP of 2 at T = 963 K and trapping the pyrolysate in solid argon at ...
Figure 6: Infrared spectrum obtained upon FVP of 3 at T = 1043 K and trapping the pyrolysate in solid argon a...
Scheme 4: Possible fragmentation pathways in the FVP of 1.
Scheme 5: Possible fragmentation pathways in the FVP of 2.
Scheme 6: Possible fragmentation pathways in the FVP of 3.
Beilstein J. Org. Chem. 2013, 9, 1296–1310, doi:10.3762/bjoc.9.146
Graphical Abstract
Scheme 1: Catalytic role of NHPI in the selective oxidation of organic substrates.
Scheme 2: Radical addition of aldehydes and analogues to alkenes.
Scheme 3: NHPI/AIBN-promoted aerobic oxidation of 2,6-diisopropylnaphthalene.
Scheme 4: NHPI/AIBN-promoted aerobic oxidation of CHB.
Scheme 5: NMBHA/MeOAMVN promoted aerobic oxidation of PUFA.
Scheme 6: Alkene dioxygenation by means of N-aryl hydroxamic acid and O2.
Scheme 7: NHPI-catalyzed reaction of adamantane under NO atmosphere.
Scheme 8: Nitration of alkanes and alkyl side-chains of aromatics.
Scheme 9: Radical mechanism for the nitration of alkanes catalyzed by NHPI.
Scheme 10: Benzyl alcohols from alkylbenzenes.
Scheme 11: Catalytic cycle of laccase-NHDs mediator oxidizing system.
Figure 1: Mediators of laccase.
Scheme 12: DADCAQ/NHPI-mediated aerobic oxidation mechanism.
Scheme 13: DADCAQ/TCNHPI mediated aerobic oxidation of ethylbenzene.
Scheme 14: NHPI/xanthone/TMAC mediated aerobic oxidation of ethylbenzene.
Scheme 15: NHPI/AQ-mediated aerobic oxidation of α-isophorone.
Scheme 16: NHPI/AQ-mediated oxidation of cellulose fibers by NaClO/NaBr system.
Scheme 17: NHPI/AQ mediated aerobic oxidation of cellulose fibers.
Scheme 18: Molecule-induced homolysis by peracids.
Scheme 19: Molecule-induced homolysis of NHPI/m- chloroperbenzoic acid system.
Scheme 20: Proposed mechanism for the NHPI/CH3CHO/O2-mediated epoxidation.
Scheme 21: NHPI/CH3CHO-mediated aerobic oxidation of alkyl aromatics.
Scheme 22: Light-induced generation of PINO from N-alkoxyphthalimides.
Scheme 23: Visible-light/g-C3N4 induced metal-free oxidation of allylic substrates.
Scheme 24: NHPI/o-phenanthroline-mediated organocatalytic system.
Scheme 25: NHPI/DMG-mediated organocatalytic system.
Scheme 26: NHPI catalyzed oxidative cleavage of C=C bonds.
Scheme 27: Synthesis of hydrazine derivatives.
Beilstein J. Org. Chem. 2013, 9, 942–950, doi:10.3762/bjoc.9.108
Graphical Abstract
Figure 1: Roseobacter clade metabolites.
Scheme 1: Degradation of DMSP via (A) demethylation pathway and (B) cleavage pathways. FH4: tetrahydrofolate.
Scheme 2: Sulfate reduction pathway and incorporation of sulfur into the amino acid pool. PAP: adenosine 3’,5...
Figure 2: Volatiles from P. gallaeciensis DSM 17395 and R. pomeroyi DSS-3. Feeding of [2H6]DMSP results in de...
Figure 3: Chromatograms of headspace extracts from P. gallaeciensis DSM 17395 after feeding of DMTeP by the u...
Figure 4: Chromatograms of headspace extracts obtained after feeding of [2H6]DMSP by the use of SPME from (A) ...
Figure 5: Chromatograms of headspace extracts from (A) R. pomeroyi DSS-3 wild type, (B) R. pomeroyi DSS-3 dmdA...
Scheme 3: Synthesis of 34S-labeled thiosulfate and sulfate.
Figure 6: Volatiles from P. gallaeciensis after feeding of selenate and selenite.
Figure 7: Chromatograms of headspace extracts from P. gallaeciensis grown on (A) 50% MB2216, (B) 50% MB2216 +...
Figure 8: Additional sulfur volatiles.
Beilstein J. Org. Chem. 2012, 8, 2025–2052, doi:10.3762/bjoc.8.229
Graphical Abstract
Figure 1: An immersion-well batch reactor with 125 W medium pressure Hg lamp.
Figure 2: Transmission profile of a 0.05 M solution, ε = 200 M−1 cm−1.
Figure 3: Schematic of a typical microflow photochemical reactor (above) and detail of a triple-channel micro...
Figure 4: Schematic of a typical macroflow photochemical reactor (above) and images of the FEP photochemical ...
Scheme 1: [2 + 2] photocycloadditions of enones with enol derivatives.
Scheme 2: Competing reactions in an intramolecular [2 + 2] photocycloaddition.
Scheme 3: Diastereocontrolled cycloaddition of a cyclic enone with cyclopentene.
Scheme 4: Comparison of yields and reaction times for a batch reactor with a microflow system.
Scheme 5: Intramolecular [2 + 2] photocycloaddition.
Scheme 6: Paterno–Büchi reaction of benzophenone with an allylic alcohol.
Scheme 7: Photooxygenation of cyclopentadiene.
Scheme 8: Preparation of the anthelmintic ascaridole 23.
Scheme 9: Production of rose oxide 27 from (−)-β-citronellol (24).
Scheme 10: Photocatalytic alkylation of benzylamine.
Scheme 11: Photocatalytic reduction of 4-nitroacetophenone.
Scheme 12: Conversion of L-lysine to L-pipecolinic acid.
Scheme 13: Photocatalytic hydrodehalogenation.
Scheme 14: Photocatalytic aza-Henry reactions.
Scheme 15: Photocatalytic α-alkylation of aliphatic ketones.
Scheme 16: Decarboxylative photochemical additions.
Scheme 17: Photochemical addition of isopropanol to furanones.
Scheme 18: Photochemical addition of methanol to limonene.
Scheme 19: Light-promoted reduction of flavone.
Scheme 20: Photoreduction of benzophenone with benzhydrol.
Scheme 21: Barton reaction in a microflow system.
Scheme 22: Microflow synthesis of vitamin D3.
Scheme 23: photochemical chlorination of cyclohexane.
Scheme 24: photochemical cyanation of pyrene.
Scheme 25: Intermolecular [2 + 2] cycloaddition of maleimide (76) and intramolecular [2 + 2] cycloaddition of ...
Scheme 26: Intramolecular [5 + 2] cycloaddition of maleimide under flow conditions.
Scheme 27: Intramolecular [5 + 2] cycloaddition as a key step in the synthesis of (±)-neostenine.
Scheme 28: In situ generation of a thioaldehyde by photolysis of a phenacyl sulfide.
Scheme 29: Photodimerisation of maleic anhydride.
Scheme 30: [2 + 2] cycloaddition of a chiral enone with ethylene.
Scheme 31: Intramolecular [2 + 2] cycloaddition of a cyclopentenone.
Scheme 32: Photochemical Wolff rearrangement and cyclisation to β-lactams.
Scheme 33: Photochemical rearrangement of aryl azides.
Scheme 34: Rearrangement of quinoline N-oxides to quinolones.
Scheme 35: Photochemical rearrangement of cyclobutenones.
Scheme 36: Photoisomerisation en route to a vitamin-D derivative.
Scheme 37: Schematic of the Seeberger photooxygenation apparatus and sensitised photooxygenation of citronello...
Scheme 38: Sensitised photooxygenation of dihydroartemisinic acid.
Scheme 39: Photochemical preparation of CpRu(MeCN)3PF6.
Scheme 40: In situ photochemical generation and reaction of a [CpRu]+ catalyst.
Scheme 41: Intermolecular alkene–alkyne coupling with photogenerated catalyst.
Scheme 42: PET deoxygenation of nucleosides.
Scheme 43: Photochemical defluorination of DABFT.
Scheme 44: Aromatic azide reduction by visible-light-mediated photocatalysis.
Scheme 45: Examples of visible-light-mediated reactions.
Scheme 46: Visible-light-mediated formation of iminium ions.
Scheme 47: Examples of visible-light-mediated photocatalytic reactions.
Scheme 48: Anhydride formation from a visible-light-mediated process.
Scheme 49: Light-mediated conjugate addition of glycosyl bromide 141 to acrolein.
Scheme 50: Visible-light-mediated photocyclisation to [5]helicene.
Beilstein J. Org. Chem. 2012, 8, 1499–1504, doi:10.3762/bjoc.8.169
Graphical Abstract
Figure 1: Synthetic methods for α-amino-β-keto esters.
Figure 2: Structures of several NHC precatalysts.
Scheme 1: Scope of aliphatic aldehydes.
Scheme 2: Cross-over experiments.
Scheme 3: Proposed reaction mechanism.
Beilstein J. Org. Chem. 2012, 8, 1208–1212, doi:10.3762/bjoc.8.134
Graphical Abstract
Scheme 1: Photolysis of cyclic carbonate esters 1a and 1b in acetonitrile.
Scheme 2: Photoreactivity of styrene glycol sulfite (8).
Scheme 3: Photochemical pathway for photoextrusion of SO2 from cyclic sulfites.
Scheme 4: Photoreactivity of meso-hydrobenzoin sulfite (9).
Beilstein J. Org. Chem. 2012, 8, 749–752, doi:10.3762/bjoc.8.85
Graphical Abstract
Figure 1: Structures of pseudopyronines A (1) and B (2) and natural oxazoles (3–8) as well as synthetic oxazo...
Figure 2: MS data from strain PB22.5, which was cultivated in [U-13C] and [U-15N] medium background and LB me...
Figure 3: All incorporated biosynthetic precursors of the oxazoles are shown in color. The nitrogen shown in ...
Beilstein J. Org. Chem. 2012, 8, 567–578, doi:10.3762/bjoc.8.64
Graphical Abstract
Figure 1: Biologically active natural products and drugs containing the piperidine ring.
Scheme 1: A general strategy to 5-nitropiperidin-2-ones and related heterocycles.
Scheme 2: The synthesis of Michael adduct model substrates for the nitro-Mannich/lactamisation cascade.
Scheme 3: Nitro-Mannich/lactamisation cascade with in situ formed imines.
Figure 2: Cyclic imines employed in nitro-Mannich/lactamisation cascade.
Scheme 4: Nitro-Mannich/lactamisation cascade of diastereomeric Michael adducts 6a, 6a’’ with cyclic imine 5a....
Scheme 5: Nitro-Mannich/lactamisation cascade with cyclic imines. aDiastereomeric ratio in a crude reaction m...
Scheme 6: Possible explanations for the observed high stereoselectivities in the nitro-Mannich/lactamisation ...
Scheme 7: Thermodynamically-driven epimerisation of 5-nitropiperidin-2-ones 2m and 2m’.
Figure 3: Thermodynamically driven epimerisation of 5-nitropiperidin-2-ones 2m and 2m’; identical diastereome...
Scheme 8: One-pot three/four-component enantioselective Michael addition/nitro-Mannich/lactamisation cascade.
Scheme 9: Protodenitration of 5-nitropiperidin-2-ones.
Scheme 10: Various reductions of denitrated heterocycles.
Beilstein J. Org. Chem. 2012, 8, 177–185, doi:10.3762/bjoc.8.19
Graphical Abstract
Figure 1: Tetrahydropyran ring containing natural products.
Scheme 1: Plausible side products mechanism.
Scheme 2: Plausible reaction mechanism via Prins cyclization.
Figure 2: Schematic NOE diagram of compound 3b.
Scheme 3: Deprotection of the hydroxy group.
Beilstein J. Org. Chem. 2011, 7, 1449–1467, doi:10.3762/bjoc.7.169
Graphical Abstract
Figure 1: Metabolic pathways in a living cell as an example of efficient coupled-reaction processes. A: Subst...
Figure 2: Four generations of biotransformations. I: Single-reaction processes; II: Single-reaction processes...
Scheme 1: Production of L-leucine (3) in a continuously operating enzyme membrane reactor (EMR). E1: L-Leucin...
Scheme 2: Production of D-mandelic acid (5) in a continuously operating enzyme membrane reactor. E1: D-(−)-Ma...
Scheme 3: Simultaneous synthesis of gluconic acid (9) and glutamic acid (8) in a continuously operated membra...
Scheme 4: Production of L-tert-leucine (11) in a continuously operated enzyme membrane reactor equipped with ...
Scheme 5: Continuous oxidation of lactose (12) to lactobionic acid (13) in a dynamic membrane-aerated reactor...
Scheme 6: Production of N-acetylneuraminic acid (17) in a continuously operated enzyme membrane reactor. E1: ...
Scheme 7: Chemo-enzymatic epoxidation of 1-methylcyclohexene (18) in a packed-bed reactor (PBR) containing No...
Scheme 8: Continuous production of (R)-1-phenylethyl propionate (24) by dynamic kinetic resolution of (rac)-1...
Scheme 9: Synthesis of D-xylulose (28) from D,L-serine (26) and D,L-glyceraldehyde (25) in a continuously ope...
Scheme 10: Continuous production of L-alanine (31) from fumarate (29) in a two-stage enzyme membrane reactor. ...
Scheme 11: Continuous synthesis of 1-phenyl-(1S,2S)-propanediol (35) in a cascade of two enzyme membrane react...
Scheme 12: Production of a dipeptide 39 in a cascade of two continuously operated membrane reactors. E1: Carbo...
Scheme 13: Continuous production of GDP-mannose (43) from mannose 1-phosphate (40) in a cascade of two enzyme ...
Scheme 14: Continuous solvent-free chemo-enzymatic synthesis of ethyl (S)-3-(benzylamino)butanoate (48) in a s...
Scheme 15: Continuous chemo-enzymatic synthesis of grossamide (52) in a cascade of packed-bed reactors. E: Per...
Scheme 16: Chemo-enzymatic synthesis of 2-aminophenoxazin-3-one (56) in a cascade of continuously operating pa...
Scheme 17: Continuous conversion of 3-phospho-D-glycerate (57) into D-ribulose 1,5-bisphosphate (58) in a casc...
Scheme 18: Continuous hydrolysis of 4-cyanopyridine (59) to isonicotinic acid (61) in a cascade of two packed-...
Scheme 19: Continuous fermentative production of ethanol (64) from hardwood lignocellulose (62) in a stirred-t...
Scheme 20: Production of hydrogen by anaerobic fermentation of glucose (7) using Clostridium acetobutylicum ce...
Scheme 21: Continuous production of (2R,5R)-hexanediol (67) in an enzyme membrane reactor containing whole cel...
Scheme 22: Synthesis of L-phenylalanine (69) in a continuously stirred tank reactor equipped with a hollow-fib...
Scheme 23: Continuous epoxidation of 1,7-octadiene (70) to (R)-7-epoxyoctene (72) by a strain of Pseudomonas o...
Scheme 24: Oxidation of styrene (73) to (S)-styrene oxide (74) in a continuously operated biofilm tube reactor...
Scheme 25: Reduction of estrone (75) to β-estradiol (76) by Saccharomyces cerevisiae in a cascade of two stirr...
Beilstein J. Org. Chem. 2011, 7, 1315–1322, doi:10.3762/bjoc.7.154
Graphical Abstract
Figure 1: Chiral diols useful for asymmetric synthesis and the tetralithio intermediate 8.
Scheme 1: Directed ortho,ortho'-dimetalation of (R,R)-hydrobenzoin (3).
Figure 2: Percentage of (R,R)-hydrobenzoin (3) (○), monodeuterohydrobenzoin (13) (■), and dideuterohydrobenzo...
Figure 3: Percentage of methylhydrobenzoin (14) (■), and dimethylhydrobenzoin (15) (Δ) as determined by 1H NM...
Scheme 2: Formation of the tetralithio intermediate 8 and the X-ray crystal structure of the bis(siloxane) 19....
Scheme 3: Reaction of the tetralithio intermediate 8 with various electrophiles.
Scheme 4: Reactions of the diiodohydrobenzoin 12 and X-ray crystal structure of the dihydrosilepin 31.
Scheme 5: Cross coupling reactions of the bis(benzoxaborol) 20 and a short formal synthesis of (R,R)-Vivol (4...
Beilstein J. Org. Chem. 2011, 7, 442–495, doi:10.3762/bjoc.7.57
Graphical Abstract
Figure 1: Structures of atorvastatin and other commercial statins.
Figure 2: Structure of compactin.
Scheme 1: Synthesis of pentasubstituted pyrroles.
Scheme 2: [3 + 2] Cycloaddition to prepare 5-isopropylpyrroles.
Scheme 3: Regiospecific [3 + 2] cycloaddition to prepare the pyrrole scaffold.
Scheme 4: Formation of the pyrrole core of atorvastatin via [3 + 2] cycloaddition.
Scheme 5: Formation of pyrrole 33 via the Paal–Knorr reaction.
Scheme 6: Convergent synthesis towards atorvastatin.
Figure 3: Binding pocket of sunitinib in the TRK KIT.
Scheme 7: Synthesis of sunitinib.
Scheme 8: Alternative synthesis of sunitinib.
Scheme 9: Key steps in the syntheses of sumatriptan and zolmitriptan.
Scheme 10: Introduction of the N,N-dimethylaminoethyl side chain.
Scheme 11: Japp–Klingemann reaction in the synthesis of sumatriptan.
Scheme 12: Synthesis of the intermediate sulfonyl chlorides 62 and 63.
Scheme 13: Alternative introduction of the sulfonamide.
Scheme 14: Negishi-type coupling to benzylic sulfonamides.
Scheme 15: Heck reaction used to introduce the sulfonamide side chain of naratriptan.
Scheme 16: Synthesis of the oxazolinone appendage of zolmitriptan.
Scheme 17: Grandberg indole synthesis used in the preparation of rizatriptan.
Scheme 18: Improved synthesis of rizatriptan.
Scheme 19: Larock-type synthesis of rizatriptan.
Scheme 20: Synthesis of eletriptan.
Scheme 21: Heck coupling for the indole system in eletriptan.
Scheme 22: Attempted Fischer indole synthesis of elatriptan.
Scheme 23: Successful Fischer indole synthesis for eletriptan.
Scheme 24: Mechanistic rationale for the Bischler–Möhlau reaction.
Scheme 25: Bischler-type indole synthesis used in the fluvastatin sodium synthesis.
Scheme 26: Palladium-mediated synthesis of ondansetron.
Scheme 27: Fischer indole synthesis of ondansetron.
Scheme 28: Optimised Pictet–Spengler reaction towards tadalafil.
Figure 4: Structures of carvedilol 136 and propranolol 137.
Scheme 29: Synthesis of the carbazole core of carvedilol.
Scheme 30: Alternative syntheses of 4-hydroxy-9H-carbazole.
Scheme 31: Convergent synthesis of etodolac.
Scheme 32: Alternative synthesis of etodolac.
Figure 5: Structures of imidazole-containing drugs.
Scheme 33: Synthesis of functionalised imidazoles towards losartan.
Scheme 34: Direct synthesis of the chlorinated imidazole in losartan.
Scheme 35: Synthesis of trisubstituted imidazoles.
Scheme 36: Preparation of the imidazole ring in olmesartan.
Scheme 37: Synthesis of ondansetron.
Scheme 38: Alternative route to ondansetron and its analogues.
Scheme 39: Proton pump inhibitors and synthesis of esomeprazole.
Scheme 40: Synthesis of benzimidazole core pantoprazole.
Figure 6: Structure of rabeprazole 194.
Scheme 41: Synthesis of candesartan.
Scheme 42: Alternative access to the candesartan key intermediate 216.
Scheme 43: .Medicinal chemistry route to telmisartan.
Scheme 44: Improved synthesis of telmisartan.
Scheme 45: Synthesis of zolpidem.
Scheme 46: Copper-catalysed 3-component coupling towards zolpidem.
Figure 7: Structure of celecoxib.
Scheme 47: Preparation of celecoxib.
Scheme 48: Alternative synthesis of celecoxib.
Scheme 49: Regioselective access to celecoxib.
Scheme 50: Synthesis of pazopanib.
Scheme 51: Syntheses of anastrozole, rizatriptan and letrozole.
Scheme 52: Regioselective synthesis of anastrozole.
Scheme 53: Triazine-mediated triazole formation towards anastrozole.
Scheme 54: Alternative routes to 1,2,4-triazoles.
Scheme 55: Initial synthetic route to sitagliptin.
Figure 8: Binding of sitagliptin within DPP-IV.
Scheme 56: The process route to sitagliptin key intermediate 280.
Scheme 57: Synthesis of maraviroc.
Scheme 58: Synthesis of alprazolam.
Scheme 59: The use of N-nitrosoamidine derivatives in the preparation of fused benzodiazepines.
Figure 9: Structures of itraconazole, ravuconazole and voriconazole.
Scheme 60: Synthesis of itraconazole.
Scheme 61: Synthesis of rufinamide.
Scheme 62: Representative tetrazole formation in valsartan.
Figure 10: Structure of tetrazole containing olmesartan, candesartan and irbesartan.
Scheme 63: Early stage introduction of the tetrazole in losartan.
Scheme 64: Synthesis of cilostazol.
Figure 11: Structure of cefdinir.
Scheme 65: Semi-synthesis of cefdinir.
Scheme 66: Thiazole syntheses towards ritonavir.
Scheme 67: Synthesis towards pramipexole.
Scheme 68: Alternative route to pramipexole.
Scheme 69: Synthesis of famotidine.
Scheme 70: Efficient synthesis of the hyperuricemic febuxostat.
Scheme 71: Synthesis of ziprasidone.
Figure 12: Structure of mometasone.
Scheme 72: Industrial access to 2-furoic acid present in mometasone.
Scheme 73: Synthesis of ranitidine from furfuryl alcohol.
Scheme 74: Synthesis of nitrofurantoin.
Scheme 75: Synthesis of benzofuran.
Scheme 76: Synthesis of amiodarone.
Scheme 77: Synthesis of raloxifene.
Scheme 78: Alternative access to the benzo[b]thiophene core of raloxifene.
Scheme 79: Gewald reaction in the synthesis of olanzapine.
Scheme 80: Alternative synthesis of olanzapine.
Figure 13: Access to simple thiophene-containing drugs.
Scheme 81: Synthesis of clopidogrel.
Scheme 82: Pictet–Spengler reaction in the preparation of tetrahydrothieno[3,2-c]pyridine (422).
Scheme 83: Alternative synthesis of key intermediate 422.
Figure 14: Co-crystal structures of timolol (left) and carazolol (right) in the β-adrenergic receptor.
Scheme 84: Synthesis of timolol.
Scheme 85: Synthesis of tizanidine 440.
Scheme 86: Synthesis of leflunomide.
Scheme 87: Synthesis of sulfamethoxazole.
Scheme 88: Synthesis of risperidone.
Figure 15: Relative abundance of selected transformations.
Figure 16: The abundance of heterocycles within top 200 drugs (5-membered rings).
Beilstein J. Org. Chem. 2011, 7, 386–393, doi:10.3762/bjoc.7.49
Graphical Abstract
Figure 1: Methods for synthesis of dibromides I and their use for preparation of 6-membered heterocycles.
Scheme 1: General methods for preparation of diols VII.
Scheme 2: General methods for preparation of tetrahydropyrans VIII.
Figure 2: Structures of 1,5-dibromomopentanes 1a–1d.
Scheme 3: Preparation of dibromides 1.
Scheme 4: Preparation of diol 2a.
Scheme 5: Preparation of diol 2b.
Scheme 6: Preparation of tetrahydropyrans 3a–3c.
Scheme 7: Preparation of tetrahydropyran 3d.
Scheme 8: Preparation of methylenetetrahydropyrans 6.
Scheme 9: Preparation of bromides 8 and 10.
Scheme 10: Preparation of sulfonium derivatives 11.
Beilstein J. Org. Chem. 2011, 7, 346–363, doi:10.3762/bjoc.7.45
Graphical Abstract
Scheme 1: Superelectrophilic activation of the acetyl cation.
Scheme 2: Ring opening of diprotonated 2-oxazolines.
Scheme 3: AlCl3-promoted ring opening of isoxaolidine 16.
Scheme 4: Ring-opening reactions of cyclopropyl derivatives.
Scheme 5: Condensations of ninhydrin (28) with benzene.
Scheme 6: Rearrangement of 29 to 30.
Scheme 7: Superacid promoted ring opening of succinic anhydride (33).
Scheme 8: Reaction of phthalic acid (36) in FSO3H-SbF5.
Scheme 9: Ring expansion of superelectrophile 42.
Scheme 10: Reaction of camphor (44) in superacid.
Scheme 11: Isomerization of 2-cyclohexen-1-one (48).
Scheme 12: Isomerization of 2-decalone (51).
Scheme 13: Rearrangement of the acyl-dication 58.
Scheme 14: Reaction of dialkylketone 64.
Scheme 15: Ozonolysis in superacid.
Scheme 16: Rearrangement of 1-hydroxy-2-methylcyclohexane carboxylic acid (79) in superacid.
Scheme 17: Isomerization of the 1,5-manxyl dication 87.
Scheme 18: Energetics of isomerization.
Scheme 19: Rearrangement of dication 90.
Scheme 20: Superacid promoted rearrangement of pivaldehyde (92).
Scheme 21: Rearrangement of a superelectrophilic carboxonium ion 100.
Scheme 22: Proposed mechanism for the Wallach rearrangement.
Scheme 23: Wallach rearrangement of azoxypyridines 108 and 109.
Scheme 24: Proposed mechanism of the benzidine rearrangement.
Scheme 25: Superacid-promoted reaction of quinine (122).
Scheme 26: Superacid-promoted reaction of vindoline derivative 130.
Scheme 27: Charge migration by hydride shift and acid–base chemistry.
Scheme 28: Reactions of 1-hydroxycyclohexanecarboxylic acid (137).
Scheme 29: Reaction of alcohol 143 with benzene in superacid.
Scheme 30: Reaction of alcohol 148 in superacid with benzene.
Scheme 31: Mechanism of aza-polycyclic aromatic compound formation.
Scheme 32: Superacid-promoted reaction of ethylene glycol (159).
Scheme 33: Reactions of 1,3-propanediol (165) and 2-methoxyethanol (169).
Scheme 34: Rearrangement of superelelctrophilic acyl dication 173.
Beilstein J. Org. Chem. 2009, 5, No. 5, doi:10.3762/bjoc.5.5
Graphical Abstract
Figure 1: Proposed reaction mechanism for the formation of Cα-tetrasubstituted tetrahydrofuran α-amino acids.
Scheme 1: Cyclisation reaction forming the tetrahydrofuran amino acid (TAA).
Figure 2: Structure of compound 15 in the solid state determined by X-ray analysis [21].
Beilstein J. Org. Chem. 2008, 4, No. 48, doi:10.3762/bjoc.4.48
Graphical Abstract
Scheme 1: Total synthesis of longifolicin by Marshall’s group.
Scheme 2: Total synthesis of corossoline by Tanaka’s group.
Scheme 3: Total synthesis of corossoline by Wu’s group.
Scheme 4: Total synthesis of pseudo-annonacin A by Hanessian’s group.
Scheme 5: Total synthesis of tonkinecin by Wu’s group.
Scheme 6: Total synthesis of gigantetrocin A by Shi’s group.
Scheme 7: Total synthesis of annonacin by Wu’s group.
Scheme 8: Total synthesis of solamin by Kitahara’s group.
Scheme 9: Total synthesis of solamin by Mioskowski’s group.
Scheme 10: Total synthesis of cis-solamin by Makabe’s group.
Scheme 11: Total synthesis of cis-solamin by Brown’s group.
Scheme 12: The formal synthesis of (+)-cis-solamin by Donohoe’s group.
Scheme 13: Total synthesis of cis-solamin by Stark’s group.
Scheme 14: Total synthesis of mosin B by Tanaka’s group.
Scheme 15: Total synthesis of longicin by Hanessian’s group.
Scheme 16: Total synthesis of murisolin and 16,19-cis-murisolin by Tanaka’s group.
Scheme 17: Synthesis of a stereoisomer library of (+)-murisolin by Curran’s group.
Scheme 18: Total synthesis of murisolin by Makabe’s group.
Scheme 19: Total synthesis of reticulatain-1 by Makabe’s group.
Scheme 20: Total synthesis of muricatetrocin C by Ley’s group.
Scheme 21: Total synthesis of (4R,12S,15S,16S,19R,20R,34S)-muricatetrocin (146) and (4R,12R,15S,16S,19R,20R,34S...
Scheme 22: Total synthesis of parviflorin by Hoye’s group.
Scheme 23: Total synthesis of parviflorin by Trost’s group.
Scheme 24: Total synthesis of trilobacin by Sinha’s group.
Scheme 25: Total synthesis of 15-epi-annonin I 181b by Scharf’s group.
Scheme 26: Total synthesis of squamocin A and squamocin D by Scharf’s group.
Scheme 27: Total synthesis of asiminocin by Marshall’s group.
Scheme 28: Total synthesis of asiminecin by Marshall’s group.
Scheme 29: Total synthesis of (+)-(30S)-bullanin by Marshall’s group.
Scheme 30: Total synthesis of uvaricin by the group of Sinha and Keinan.
Scheme 31: Formal synthesis of uvaricin by Burke’s group.
Scheme 32: Total synthesis of trilobin by Marshall’s group.
Scheme 33: Total synthesis of trilobin by the group of Sinha and Keinan.
Scheme 34: Total synthesis of asimilobin by the group of Wang and Shi.
Scheme 35: Total synthesis of squamotacin by the group of Sinha and Keinan.
Scheme 36: Total synthesis of asimicin by Marshall’s group.
Scheme 37: Total synthesis of asimicin by the group of Sinha and Keinan.
Scheme 38: Total synthesis of asimicin by Roush’s group.
Scheme 39: Total synthesis of asimicin by Marshall’s group.
Scheme 40: Total synthesis of 10-hydroxyasimicin by Ley’s group.
Scheme 41: Total synthesis of asimin by Marshall’s group.
Scheme 42: Total synthesis of bullatacin by the group of Sinha and Keinan.
Scheme 43: Total synthesis of bullatacin by Roush’s group.
Scheme 44: Total synthesis of bullatacin by Pagenkopf’s group.
Scheme 45: Total synthesis of rollidecins C and D by the group of Sinha and Keinan.
Scheme 46: Total synthesis of 30(S)-hydroxybullatacin by Marshall’s group.
Scheme 47: Total synthesis of uvarigrandin A and 5(R)-uvarigrandin A by Marshall’s group.
Scheme 48: Total synthesis of membranacin by Brown’s group.
Scheme 49: Total synthesis of membranacin by Lee’s group.
Scheme 50: Total synthesis of rolliniastatin 1 and rollimembrin by Lee’s group.
Scheme 51: Total synthesis of longimicin D by the group of Maezaki and Tanaka.
Scheme 52: Total synthesis of the structure proposed for mucoxin by Borhan’s group.
Scheme 53: Modular synthesis of adjacent bis-THF annonaceous acetogenins by Marshall’s group.
Scheme 54: Total synthesis of 4-deoxygigantecin by Tanaka’s group.
Scheme 55: Total synthesis of squamostatins D by Marshall’s group.
Scheme 56: Total synthesis of gigantecin by Crimmins’s group.
Scheme 57: Total synthesis of gigantecin by Hoye’s group.
Scheme 58: Total synthesis of cis-sylvaticin by Donohoe’s group.
Scheme 59: Total synthesis of 17(S),18(S)-goniocin by Sinha’s group.
Scheme 60: Total synthesis of goniocin and cyclogoniodenin T by the group of Sinha and Keinan.
Scheme 61: Total synthesis of jimenezin by Takahashi’s group.
Scheme 62: Total synthesis of jimenezin by Lee’s group.
Scheme 63: Total synthesis of jimenezin by Hoffmann’s group.
Scheme 64: Total synthesis of muconin by Jacobsen’s group.
Scheme 65: Total synthesis of (+)-muconin by Kitahara’s group.
Scheme 66: Total synthesis of muconin by Takahashi’s group.
Scheme 67: Total synthesis of muconin by the group of Yoshimitsu and Nagaoka.
Scheme 68: Total synthesis of mucocin by the group of Sinha and Keinan.
Scheme 69: Total synthesis of mucocin by Takahashi’s group.
Scheme 70: Total synthesis of (−)-mucocin by Koert’s group.
Scheme 71: Total synthesis of mucocin by the group of Takahashi and Nakata.
Scheme 72: Total synthesis of mucocin by Evans’s group.
Scheme 73: Total synthesis of mucocin by Mootoo’s group.
Scheme 74: Total synthesis of (−)-mucocin by Crimmins’s group.
Scheme 75: Total synthesis of pyranicin by the group of Takahashi and Nakata.
Scheme 76: Total synthesis of pyranicin by Rein’s group.
Scheme 77: Total synthesis of proposed pyragonicin by the group of Takahashi and Nakata.
Scheme 78: Total synthesis of pyragonicin by Rein’s group.
Scheme 79: Total synthesis of pyragonicin by Takahashi’s group.
Scheme 80: Total synthesis of squamostanal A by Figadère’s group.
Scheme 81: Total synthesis of diepomuricanin by Tanaka’s group.
Scheme 82: Total synthesis of (−)-muricatacin [(R,R)-373a] and its enantiomer (+)-muricatacin [(S,S)-373b] by ...
Scheme 83: Total synthesis of epi-muricatacin (+)-(S,R)-373c and (−)-(R,S)-373d by Scharf’s group.
Scheme 84: Total synthesis of (−)-muricatacin 373a and 5-epi-(−)-muricatacin 373d by Uang’s group.
Scheme 85: Total synthesis of four stereoisomers of muricatacin by Yoon’s group.
Scheme 86: Total synthesis of (+)-muricatacin by Figadère’s group.
Scheme 87: Total synthesis of (+)-epi-muricatacin and (−)-muricatacin by Couladouros’s group.
Scheme 88: Total synthesis of muricatacin by Trost’s group.
Scheme 89: Total synthesis of (−)-(4R,5R)-muricatacin by Heck and Mioskowski’s group.
Scheme 90: Total synthesis of muricatacin (−)-373a by the group of Carda and Marco.
Scheme 91: Total synthesis of (−)- and (+)-muricatacin by Popsavin’s group.
Scheme 92: Total synthesis of (−)-muricatacin by the group of Bernard and Piras.
Scheme 93: Total synthesis of (−)-muricatacin by the group of Yoshimitsu and Nagaoka.
Scheme 94: Total synthesis of (−)-muricatacin by Quinn’s group.
Scheme 95: Total synthesis of montecristin by Brückner’s group.
Scheme 96: Total synthesis of (−)-acaterin by the group of Franck and Figadère.
Scheme 97: Total synthesis of (−)-acaterin by Singh’s group.
Scheme 98: Total synthesis of (−)-acaterin by Kumar’s group.
Scheme 99: Total synthesis of rollicosin by Quinn’s group.
Scheme 100: Total synthesis of Rollicosin by Makabe’s group.
Scheme 101: Total synthesis of squamostolide by Makabe’s group.
Scheme 102: Total synthesis of tonkinelin by Makabe’s group.